Table 1.
Demographic, staging, and treatment characteristics of study population
| Characteristic | Overall | BRCA2‐mutated patients | ATM‐mutated patients | p Value |
|---|---|---|---|---|
| N | 158 | 100 | 58 | |
| Median age at first taxane or PARP inhibitor therapy, years (interquartile range) | 72 (62−72) | 66 (60−71) | 69 (63−74) | <0.01 |
| Gleason sum at diagnosis (%) | 0.34 | |||
| 8−10 | 107 (75%) | 69 (78%) | 38 (70%) | |
| 6−7 | 36 (25%) | 20 (22%) | 16 (30%) | |
| Unknown | 15 | 11 | 4 | |
| M1 disease at initial diagnosis (%) | 0.37 | |||
| Yes | 70 (44%) | 47 (47%) | 23 (40%) | |
| No | 88 (56%) | 53 (53%) | 35 (60%) | |
| Presence of bone metastases | 0.04 | |||
| Yes | 132 (84%) | 79 (79%) | 53 (91%) | |
| No | 26 (16%) | 21 (21%) | 5 (9%) | |
| Presence of nodal metastases | 0.25 | |||
| Yes | 99 (63%) | 66 (66%) | 33 (57%) | |
| No | 59 (37%) | 34 (34%) | 25 (43%) | |
| Presence of liver metastases | 0.32 | |||
| Yes | 35 (22%) | 25 (25%) | 10 (17%) | |
| No | 123 (78%) | 75 (75%) | 48 (83%) | |
| Presence of lung metastases | 0.43 | |||
| Yes | 35 (22%) | 20 (20%) | 15 (26%) | |
| No | 123 (78%) | 80 (80%) | 43 (74%) | |
| Prior enzalutamide therapy | 0.68 | |||
| Yes | 96 (61%) | 62 (62%) | 34 (59%) | |
| No | 62 (39%) | 39 (38%) | 24 (41%) | |
| Prior abiraterone therapy | 0.61 | |||
| Yes | 126 (80%) | 81 (81%) | 45 (78%) | |
| No | 32 (20%) | 19 (19%) | 13 (22%) | |
| Taxane and PARP inhibitor treatment pattern | <0.001 | |||
| Taxane only | 51 (32%) | 21 (21%) | 30 (52%) | |
| PARP inhibitor only | 38 (24%) | 29 (29%) | 9 (16%) | |
| Taxane first, then PARP inhibitor | 44 (28%) | 30 (30%) | 14 (24%) | |
| PARP inhibitor first, then taxane | 25 (16%) | 20 (20%) | 5 (9%) | |
Abbreviation: PARP, poly(ADP‐ribose) polymerase.